Dopastatin second generation

Drug Profile

Dopastatin second generation

Alternative Names: BIM 065

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator Ipsen
  • Class Antineoplastics; Catecholamines; Cyclic peptides; Pancreatic hormones; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Corticotropin-releasing factor antagonists; Dopamine D1 receptor agonists; Growth hormone releasing factor agonists; Growth hormone releasing factor antagonists; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Acromegaly; Pituitary ACTH hypersecretion; Pituitary cancer

Most Recent Events

  • 18 Aug 2015 Phase-I clinical trials in Acromegaly in France (Parenteral)
  • 18 Aug 2015 Phase-I clinical trials in Pituitary ACTH Hypersecretion in France (Parenteral)
  • 18 Aug 2015 Phase-I clinical trials in Pituitary cancer in France (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top